Despite the pandemic, 34,154 migrants, refugees or asylum-seekers landed in Sicily (Italy) in 2020, representing the main point of entry by sea into Europe. The SARS-CoV-2 surveillance program among migrants arriving to Sicily via the Mediterranean Sea, made by the combination of clinical examination and molecular testing, has been integrated by full-genome sequencing strains using the NGS technology from the last week of February. To date, more than one hundred full-genome strains have been sequenced and 8 different lineages have been identified mostly belonging to the lineages B.1.1.7 and B.1.525. As global access to COVID-19 vaccines should be ensured, the need to provide more detailed information to inform policies and to drive the possible re-engineering of vaccines needed to deal with the challenge of new and future variants should be highlighted.
The dual/global value of SARS-COV- 2 genome surveillance on migrants arriving to Europe via the mediterranean routes / Marotta, C.; Stefanelli, P.; Tramuto, F.; Angeloni, U.; Maida, C. M.; Cernigliaro, A.; Barone, T.; Vitale, F.; Rezza, G.; Mazzucco, W.. - In: ANNALS OF GLOBAL HEALTH. - ISSN 2214-9996. - 87:1(2021), pp. 1-5. [10.5334/aogh.3425]
The dual/global value of SARS-COV- 2 genome surveillance on migrants arriving to Europe via the mediterranean routes
Rezza G.Penultimo
;
2021-01-01
Abstract
Despite the pandemic, 34,154 migrants, refugees or asylum-seekers landed in Sicily (Italy) in 2020, representing the main point of entry by sea into Europe. The SARS-CoV-2 surveillance program among migrants arriving to Sicily via the Mediterranean Sea, made by the combination of clinical examination and molecular testing, has been integrated by full-genome sequencing strains using the NGS technology from the last week of February. To date, more than one hundred full-genome strains have been sequenced and 8 different lineages have been identified mostly belonging to the lineages B.1.1.7 and B.1.525. As global access to COVID-19 vaccines should be ensured, the need to provide more detailed information to inform policies and to drive the possible re-engineering of vaccines needed to deal with the challenge of new and future variants should be highlighted.File | Dimensione | Formato | |
---|---|---|---|
3425-1-13082-1-10-20210721.pdf
accesso aperto
Tipologia:
PDF editoriale (versione pubblicata dall'editore)
Licenza:
Creative commons
Dimensione
759.78 kB
Formato
Adobe PDF
|
759.78 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.